Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, et al. Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1. Clin Cancer Res 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-1198.
PMID: 40788187